prednisone has been researched along with Cardiovascular Diseases in 50 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Those treated with tacrolimus had lower, not significant, prevalence of hypertension, hyperuricemia, hypoalbuminemia, hypercholesterolemia, hypertriglyceridemia, and low serum HDL-cholesterol than those treated with sirolimus and cyclosporine." | 3.83 | Effect of Immunosuppressive Therapy on Cardiovascular Risk Factor Prevalence in Kidney-Transplanted Children: Comparative Study. ( Camarena-Arias, PA; García-Bello, JA; Mendoza-Gómez, E; Romo-Del Río, EG; Santos-Caballero, M, 2016) |
| "An observational population-based cohort study was performed to investigate the role of comorbidity on outcome and treatment-related toxicity in patients with newly diagnosed advanced-stage diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)." | 3.80 | Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study. ( Beerden, T; Boslooper, K; Hoogendoorn, M; Joosten, P; Kibbelaar, RE; Kluin-Nelemans, HC; Storm, H; van Kamp, H; van Rees, B; van Roon, EN; Veeger, NJ; Veldhuis, GJ; Wieringa, A, 2014) |
| " No grade 3-4 adverse events were observed." | 2.80 | Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. ( de Braud, F; Grassi, P; Procopio, G; Salvioni, R; Testa, I; Torri, V; Valdagni, R; Verzoni, E, 2015) |
| "Severe infections were seen as often with VBMCP as with VBMCP + rIFN(alpha2) (13% vs." | 2.69 | The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. ( Greipp, PR; Kay, NE; Keimowitz, RM; Kyle, RA; Lenhard, RE; Leong, T; Oken, MM; Van Ness, B, 1999) |
| "Patients treated for non-Hodgkin lymphoma are at risk of cardiovascular adverse events, with the risk of heart failure being particularly high." | 2.66 | Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis. ( Asselbergs, FW; Bosman, LP; Cramer, MJ; Doevendans, PA; Kamphuis, JAM; Linschoten, M; Teske, AJ; van Rhenen, A, 2020) |
| "Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) that compromise quality of life and may increase mortality." | 1.48 | Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease. ( Bewtra, M; Brensinger, CM; Chen, L; Curtis, JR; Lewis, JD; Mamtani, R; Osterman, MT; Roy, JA; Scott, FI; Xie, F; Yun, H, 2018) |
| "Advances in anti-lymphoma therapy prolong overall survival, making late adverse effects, like doxorubicin-related cardiotoxicity, an even more important clinical issue." | 1.48 | Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP Regimen. ( Długosz-Danecka, M; Gruszka, AM; Jaroszyński, A; Jurczak, W; Krawczyk, K; Ogórka, T; Olszanecka, A; Skotnicki, AB; Sobociński, M; Szmit, S, 2018) |
| " For the cumulative dose of glucocorticoids, the minimum dosage associated with all-cause mortality was 40 gm (HR 1." | 1.40 | Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. ( Battafarano, DF; del Rincón, I; Erikson, JM; Escalante, A; Restrepo, JF, 2014) |
| " Steroid dosing may be a modifiable risk factor." | 1.39 | Association between steroid dosage and death with a functioning graft after kidney transplantation. ( Döhler, B; Opelz, G, 2013) |
| "The majority of patients with Hodgkin's disease can be cured by combination of polychemotherapy and radiotherapy (RT) that can produce late toxic pulmonary and cardiac effects which often remain at a subclinical level." | 1.36 | Cardiopulmonary toxicity of different chemoradiotherapy combined regimens for Hodgkin's disease. ( Bonfante, V; Busia, A; Laffranchi, A; Villani, F; Viviani, S, 2010) |
| "Therefore, 126 patients suffering from Hodgkin's disease were investigated after a follow-up of at least 5 years from the completion of the combined treatment." | 1.35 | Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease. ( Bonfante, V; Busia, A; Laffranchi, A; Villani, F; Villani, M; Viviani, S, 2009) |
| "The obstructive hypertrophic cardiomyopathy is characterised by a pronounced cardiomegaly, insufficient weight gain as well as dyspnea and cyanosis." | 1.26 | [Endocardial fibroelastosis (E.F.) and its differential diagnosis]. ( Rossi, E, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (32.00) | 18.7374 |
| 1990's | 4 (8.00) | 18.2507 |
| 2000's | 7 (14.00) | 29.6817 |
| 2010's | 17 (34.00) | 24.3611 |
| 2020's | 6 (12.00) | 2.80 |
| Authors | Studies |
|---|---|
| Juul, MB | 1 |
| Jelicic, J | 1 |
| Anru, PL | 1 |
| Engberg, H | 1 |
| Hammershøj Jensen, P | 1 |
| Kristensen, HB | 1 |
| Baech, J | 2 |
| Clausen, MR | 2 |
| Gang, AO | 2 |
| Munksgaard, L | 1 |
| El-Galaly, TC | 2 |
| Frederiksen, H | 2 |
| Stauffer Larsen, T | 1 |
| Severinsen, MT | 1 |
| Øvlisen, AK | 1 |
| Vestergaard, P | 1 |
| Torp-Pedersen, C | 1 |
| Jørgensen, J | 1 |
| Poulsen, CB | 1 |
| Brown, P | 1 |
| Pedersen, RS | 1 |
| Ekström Smedby, K | 1 |
| Eloranta, S | 1 |
| Jakobsen, LH | 1 |
| Karpouzas, GA | 1 |
| Papotti, B | 1 |
| Ormseth, SR | 1 |
| Palumbo, M | 1 |
| Hernandez, E | 1 |
| Adorni, MP | 1 |
| Zimetti, F | 1 |
| Budoff, MJ | 1 |
| Ronda, N | 1 |
| Linschoten, M | 1 |
| Kamphuis, JAM | 1 |
| van Rhenen, A | 1 |
| Bosman, LP | 1 |
| Cramer, MJ | 1 |
| Doevendans, PA | 1 |
| Teske, AJ | 1 |
| Asselbergs, FW | 1 |
| Roubille, C | 1 |
| Coffy, A | 1 |
| Rincheval, N | 1 |
| Dougados, M | 1 |
| Flipo, RM | 1 |
| Daurès, JP | 1 |
| Combe, B | 1 |
| Ocon, AJ | 1 |
| Reed, G | 1 |
| Pappas, DA | 1 |
| Curtis, JR | 3 |
| Kremer, JM | 2 |
| Lewis, JD | 1 |
| Scott, FI | 1 |
| Brensinger, CM | 1 |
| Roy, JA | 1 |
| Osterman, MT | 1 |
| Mamtani, R | 1 |
| Bewtra, M | 1 |
| Chen, L | 1 |
| Yun, H | 1 |
| Xie, F | 1 |
| Długosz-Danecka, M | 1 |
| Gruszka, AM | 1 |
| Szmit, S | 1 |
| Olszanecka, A | 1 |
| Ogórka, T | 1 |
| Sobociński, M | 1 |
| Jaroszyński, A | 1 |
| Krawczyk, K | 1 |
| Skotnicki, AB | 1 |
| Jurczak, W | 1 |
| Opelz, G | 1 |
| Döhler, B | 1 |
| Fangtham, M | 1 |
| Petri, M | 2 |
| Procopio, G | 1 |
| Grassi, P | 1 |
| Testa, I | 1 |
| Verzoni, E | 1 |
| Torri, V | 1 |
| Salvioni, R | 1 |
| Valdagni, R | 1 |
| de Braud, F | 1 |
| del Rincón, I | 1 |
| Battafarano, DF | 1 |
| Restrepo, JF | 1 |
| Erikson, JM | 1 |
| Escalante, A | 1 |
| Wieringa, A | 1 |
| Boslooper, K | 1 |
| Hoogendoorn, M | 1 |
| Joosten, P | 1 |
| Beerden, T | 1 |
| Storm, H | 1 |
| Kibbelaar, RE | 1 |
| Veldhuis, GJ | 1 |
| van Kamp, H | 1 |
| van Rees, B | 1 |
| Kluin-Nelemans, HC | 1 |
| Veeger, NJ | 1 |
| van Roon, EN | 1 |
| Bichile, T | 1 |
| Taber, DJ | 1 |
| Douglass, K | 1 |
| Srinivas, T | 1 |
| McGillicuddy, JW | 1 |
| Bratton, CF | 1 |
| Chavin, KD | 1 |
| Baliga, PK | 1 |
| Egede, LE | 1 |
| Chamienia, A | 1 |
| Dębska-Ślizień, A | 1 |
| Król, E | 1 |
| Biedunkiewicz, B | 1 |
| Rutkowski, B | 1 |
| Solomon, DH | 1 |
| Greenberg, J | 1 |
| Liu, M | 1 |
| Farkouh, ME | 1 |
| Tsao, P | 1 |
| Etzel, CJ | 1 |
| García-Bello, JA | 1 |
| Romo-Del Río, EG | 1 |
| Mendoza-Gómez, E | 1 |
| Camarena-Arias, PA | 1 |
| Santos-Caballero, M | 1 |
| Laribi, K | 1 |
| Denizon, N | 1 |
| Bolle, D | 1 |
| Truong, C | 1 |
| Besançon, A | 1 |
| Sandrini, J | 1 |
| Anghel, A | 1 |
| Farhi, J | 1 |
| Ghnaya, H | 1 |
| Baugier de Materre, A | 1 |
| Villani, F | 2 |
| Busia, A | 2 |
| Villani, M | 1 |
| Laffranchi, A | 2 |
| Viviani, S | 2 |
| Bonfante, V | 2 |
| Aghdassi, E | 1 |
| Ma, DW | 1 |
| Morrison, S | 1 |
| Hillyer, LM | 1 |
| Clarke, S | 1 |
| Gladman, DD | 1 |
| Urowitz, MB | 1 |
| Fortin, PR | 1 |
| Schmitt, CJ | 1 |
| Dietrich, S | 1 |
| Ho, AD | 1 |
| Witzens-Harig, M | 1 |
| Vacher-Coponat, H | 1 |
| Moal, V | 1 |
| Indreies, M | 1 |
| Purgus, R | 1 |
| Loundou, A | 1 |
| Burtey, S | 1 |
| Brunet, P | 1 |
| Moussi-Frances, J | 1 |
| Daniel, L | 1 |
| Dussol, B | 1 |
| Berland, Y | 1 |
| Lemieux, I | 1 |
| Houde, I | 1 |
| Pascot, A | 1 |
| Lachance, JG | 1 |
| Noël, R | 1 |
| Radeau, T | 1 |
| Després, JP | 1 |
| Bergeron, J | 1 |
| PINES, I | 1 |
| BARACCHI, G | 1 |
| PRIVITERA, A | 1 |
| CATELLI, P | 1 |
| NIEVEEN, J | 1 |
| SIEGENTHALER, W | 1 |
| SIEGENTHALER, G | 1 |
| BONER, A | 1 |
| CATALANO, TC | 1 |
| SORBINI, CA | 1 |
| VALORI, C | 1 |
| GRASSI, V | 1 |
| EDEIKEN, J | 1 |
| BASS, H | 1 |
| Dessein, PH | 1 |
| Joffe, BI | 1 |
| Stanwix, AE | 1 |
| Christian, BF | 1 |
| Veller, M | 1 |
| Hohage, H | 1 |
| Welling, U | 1 |
| Heck, M | 1 |
| Zeh, M | 1 |
| Gerhardt, U | 1 |
| Suwelack, BM | 1 |
| Hogg, RJ | 1 |
| Cruzado, JM | 1 |
| Bestard, O | 1 |
| Riera, L | 1 |
| Torras, J | 1 |
| Gil-Vernet, S | 1 |
| Serón, D | 1 |
| Rama, I | 1 |
| Moreso, F | 1 |
| Martínez-Castelao, A | 1 |
| Grinyó, JM | 1 |
| Georgiadis, AN | 1 |
| Voulgari, PV | 1 |
| Argyropoulou, MI | 1 |
| Alamanos, Y | 1 |
| Elisaf, M | 1 |
| Tselepis, AD | 1 |
| Drosos, AA | 1 |
| Schlichting, P | 1 |
| Christensen, E | 1 |
| Fauerholdt, L | 1 |
| Poulsen, H | 1 |
| Juhl, E | 1 |
| Tygstrup, N | 1 |
| Sonneveld, P | 1 |
| de Ridder, M | 1 |
| van der Lelie, H | 1 |
| Nieuwenhuis, K | 1 |
| Schouten, H | 1 |
| Mulder, A | 1 |
| van Reijswoud, I | 1 |
| Hop, W | 1 |
| Lowenberg, B | 1 |
| Kronenberg, F | 1 |
| Königsrainer, A | 1 |
| Lhotta, K | 1 |
| Margreiter, R | 1 |
| Dieplinger, H | 1 |
| König, P | 1 |
| Oken, MM | 1 |
| Leong, T | 1 |
| Lenhard, RE | 1 |
| Greipp, PR | 1 |
| Kay, NE | 1 |
| Van Ness, B | 1 |
| Keimowitz, RM | 1 |
| Kyle, RA | 1 |
| Rossi, E | 1 |
| Sewell, KL | 1 |
| Hancock, SL | 1 |
| Hoppe, RT | 1 |
| Horning, SJ | 1 |
| Rosenberg, SA | 1 |
| Haugen, OA | 1 |
| Buchanan, EC | 1 |
| Brooks, MR | 1 |
| Greenwood, RB | 1 |
| Black, DA | 1 |
| Rose, G | 1 |
| Brewer, DB | 1 |
| Langley, ML | 1 |
| Fiegel, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Etude et Suivi Des POlyarthrites Indifférenciées Récentes[NCT03666091] | 813 participants (Actual) | Observational | 2002-11-13 | Active, not recruiting | |||
| Steroid Withdrawal and Novo Donor-specific Anti-HLA Antibodies in Renal Transplant Patients: a Prospective, Randomized and Controlled Study in Parallel Groups[NCT02284464] | Phase 4 | 230 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone[NCT03187743] | 72 participants (Actual) | Interventional | 2018-04-17 | Completed | |||
| The Effect of Prednisone on Atherogenesis as Studied in the Macrophage Foam Cell Formation Model System.[NCT03367663] | Early Phase 1 | 10 participants (Actual) | Interventional | 2018-01-17 | Completed | ||
| Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma[NCT02526823] | Phase 4 | 360 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | ||
| Phase I Study of Pegylated Liposomal Doxorubicin Combined With Cyclophosphamide and Vincristine in Treatment Progress, Relapse, and Refractory Solid Tumors in Children[NCT04213612] | Phase 1 | 21 participants (Anticipated) | Interventional | 2019-12-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measurements of DSA at baseline, and at 3, 6, 12, 18 and 24 months (NCT02284464)
Timeframe: 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Steroids, Tacrolimus and Mycophenolate | 0 |
| Tacrolimus and Mycophenolate | 0 |
Graft survival after kidney transplant in both groups (NCT02284464)
Timeframe: 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Steroids, Tacrolimus and Mycophenolate | 39 |
| Tacrolimus and Mycophenolate | 36 |
Incidence of diabetes mellitus after kidney transplant in both groups at 1, 2, 3, 4, 6, 9, 12, 18 and 24 months (NCT02284464)
Timeframe: 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Steroids, Tacrolimus and Mycophenolate | 10 |
| Tacrolimus and Mycophenolate | 6 |
Patients with acute rejection lesions (including subclinical rejection) at 24 months according to Banff classification (NCT02284464)
Timeframe: 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Steroids, Tacrolimus and Mycophenolate | 2 |
| Tacrolimus and Mycophenolate | 3 |
Patient survival after kidney transplant in both groups (NCT02284464)
Timeframe: 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Steroids, Tacrolimus and Mycophenolate | 39 |
| Tacrolimus and Mycophenolate | 36 |
Renal function after kidney transplant in both groups at 24 months measured according to the creatinine (mg/dL) concentrations (NCT02284464)
Timeframe: 24 months
| Intervention | mg/dl (Mean) |
|---|---|
| Steroids, Tacrolimus and Mycophenolate | 1.34 |
| Tacrolimus and Mycophenolate | 1.4 |
Renal function after kidney transplant in both groups at 24 months measured according to the proteinuria (mg/24 h) concentrations (NCT02284464)
Timeframe: 24 months
| Intervention | mg/24h (Mean) |
|---|---|
| Steroids, Tacrolimus and Mycophenolate | 209 |
| Tacrolimus and Mycophenolate | 148 |
The Basle scale was used to assess adherence (BAASIS questionnaire) to immunosuppressive therapy. (NCT02284464)
Timeframe: At 24 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Forgot at least one dose during last 4 weeks | Dose taken 2 hours or more before or after time | |
| Steroids, Tacrolimus and Mycophenolate | 0 | 3 |
| Tacrolimus and Mycophenolate | 1 | 11 |
Blood pressure after kidney transplant in both groups at 24 months (NCT02284464)
Timeframe: 24 months
| Intervention | mmHg (Mean) | |
|---|---|---|
| Systolic BP | Diastolic BP | |
| Steroids, Tacrolimus and Mycophenolate | 133 | 74.9 |
| Tacrolimus and Mycophenolate | 125 | 76 |
Lipid profile after kidney transplant in both groups at 24 months (NCT02284464)
Timeframe: 24 months
| Intervention | mg/dl (Mean) | |||
|---|---|---|---|---|
| Cholesterol | HDL | LDL | Triglycerides | |
| Steroids, Tacrolimus and Mycophenolate | 164 | 51 | 86 | 140 |
| Tacrolimus and Mycophenolate | 161 | 44.7 | 92 | 127 |
Measurement at 24 months according to the Banff classification. The Banff Classification of Allograft Pathology is an international consensus classification for the reporting of biopsies from solid organ transplant. The scale ranges from 0 to 3, 3 being the worst. (NCT02284464)
Timeframe: 24 months
| Intervention | score on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interstitial fibrosis and tubular atrophy | Chronic graft lesion | Glomerulitis | Peritubular capillaritis | Tubulitis | Interstitial inflammation | Arteritis | Interstitial fibrosis | Tubular atrophy | Graft glomerulopathy | Chronic vascular lesions | Arteriolar hyalinosis | |
| Steroids, Tacrolimus and Mycophenolate | 1.18 | 1.96 | 0.17 | 0.24 | 0.5 | 0.82 | 0 | 0.6 | 0.6 | 0.14 | 0.58 | 0.53 |
| Tacrolimus and Mycophenolate | 1.83 | 2.6 | 0.08 | 0.20 | 0.56 | 0.68 | 0 | 0.88 | 0.88 | 0 | 0.64 | 0.69 |
5 reviews available for prednisone and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Cyclophosphamide; Doxorubic | 2020 |
2013 update: Hopkins lupus cohort.
Topics: Antirheumatic Agents; Cardiovascular Diseases; Cognition Disorders; Cohort Studies; Creatinine; Gluc | 2013 |
Prevention and management of co-morbidities in SLE.
Topics: Adrenal Cortex Hormones; Cardiovascular Diseases; Comorbidity; Humans; Lupus Erythematosus, Systemic | 2014 |
[TREATMENT OF KIDNEY DISEASES, CARDIAC AND VASCULAR DISORDERS AS WELL AS COLLAGENOSES WITH CORTISONES].
Topics: Adams-Stokes Syndrome; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Arthritis, Rheumatoid; | 1964 |
Adolescents with proteinuria and/or the nephrotic syndrome.
Topics: Adolescent; Cardiovascular Diseases; Comorbidity; Glucocorticoids; Humans; Nephrotic Syndrome; Predn | 2005 |
10 trials available for prednisone and Cardiovascular Diseases
| Article | Year |
|---|---|
Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Agents; Cardiovascular Diseases; Comorb | 2015 |
Open prospective study to evaluate cardiovascular risk factors and renal function in 2 dosage regimens of tacrolimus combined with mycophenolate mofetil and steroids in renal transplant patients: 5-year results.
Topics: Adolescent; Adult; Aged; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combin | 2014 |
A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
Topics: Adult; Antilymphocyte Serum; Azathioprine; Cardiovascular Diseases; Cohort Studies; Cyclosporine; Dr | 2012 |
Effects of prednisone withdrawal on the new metabolic triad in cyclosporine-treated kidney transplant patients.
Topics: Anti-Inflammatory Agents; Apolipoproteins B; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, | 2002 |
Conversion from cyclosporine to tacrolimus after renal transplantation improves cardiovascular risk factors.
Topics: Adult; Cardiovascular Diseases; Cholesterol; Creatinine; Cyclosporine; Female; Glomerular Filtration | 2005 |
Main causes of death in cirrhosis.
Topics: Bacterial Infections; Cardiovascular Diseases; Clinical Trials as Topic; Female; Gastrointestinal He | 1983 |
Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined | 1995 |
The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Disea | 1999 |
Intercurrent death after Hodgkin disease therapy in radiotherapy and adjuvant MOPP trials.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Clinica | 1988 |
Controlled trial of prednisone in adult patients with the nephrotic syndrome.
Topics: Adolescent; Adult; Aged; Biopsy; Cardiovascular Diseases; Clinical Trials as Topic; Female; Glomerul | 1970 |
35 other studies available for prednisone and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiovascular diseases in elderly survivors of diffuse large B-cell lymphoma: a Danish population-based cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Cohort Studies; Cyclo | 2022 |
Risk of diabetes and the impact on preexisting diabetes in patients with lymphoma treated with steroid-containing immunochemotherapy.
Topics: Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus; Humans; Insulins; Lymphoma, Non-Hodgkin; | 2022 |
ATP-binding cassette G1 membrane transporter-mediated cholesterol efflux capacity influences coronary atherosclerosis and cardiovascular risk in Rheumatoid Arthritis.
Topics: Adenosine Triphosphate; Animals; Arthritis, Rheumatoid; Cardiovascular Diseases; CHO Cells; Choleste | 2023 |
Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Blood Sedimentation; Cardiovascular Diseases; Female; Fractures, Bone; | 2021 |
Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis.
Topics: Acute Coronary Syndrome; Adult; Aged; Angina, Unstable; Antirheumatic Agents; Arrhythmias, Cardiac; | 2021 |
Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Cardiovas | 2018 |
Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP Regimen.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzym | 2018 |
Association between steroid dosage and death with a functioning graft after kidney transplantation.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Cardiovascular Diseases; Female; Graft Rejection; Graft | 2013 |
Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Dose-Response Relationship, Drug; Female; Glu | 2014 |
Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2014 |
Significant racial differences in the key factors associated with early graft loss in kidney transplant recipients.
Topics: Adult; Aged; BK Virus; Black or African American; Cardiovascular Diseases; Cohort Studies; Dyslipide | 2014 |
Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a Consortium of Rheumatology Researchers of North America Registry Study.
Topics: Adult; Age Factors; Aged; Arthritis, Rheumatoid; Cardiovascular Diseases; Cohort Studies; Comorbidit | 2015 |
Effect of Immunosuppressive Therapy on Cardiovascular Risk Factor Prevalence in Kidney-Transplanted Children: Comparative Study.
Topics: Adolescent; Adult; Cardiovascular Diseases; Child; Cyclosporine; Female; Humans; Hypertension; Hyper | 2016 |
R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Cyclopho | 2016 |
Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cardiovascular Diseases; Com | 2009 |
Cardiopulmonary toxicity of different chemoradiotherapy combined regimens for Hodgkin's disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cardiovascular Diseases; Com | 2010 |
Alterations in circulating fatty acid composition in patients with systemic lupus erythematosus: a pilot study.
Topics: Adult; Anti-Inflammatory Agents; Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Dise | 2011 |
Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular D | 2012 |
Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular D | 2012 |
Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular D | 2012 |
Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular D | 2012 |
[So-called activity of balance of several cardiovascular medicinal agents].
Topics: Cardiovascular Agents; Cardiovascular Diseases; Humans; Prednisone; Reserpine | 1957 |
[ON 2 CASES OF COMPLETE ATRIOVENTRICULAR BLOCK (ACUTE AND REVERSIBLE) CAUSED BY RHEUMATIC MYOCARDITIS].
Topics: Adolescent; Adrenocorticotropic Hormone; Atrioventricular Block; Cardiovascular Diseases; Electrocar | 1963 |
[EFFICACY OF PREDNISONE CURE IN A CASE OF ATRIAL FIBRILLATION DURING THE COURSE OF PEMPHIGUS AND ITS POSSIBLE SIGNIFICANCE].
Topics: Atrial Fibrillation; Cardiovascular Diseases; Digitalis Glycosides; Humans; Pemphigus; Prednisone | 1964 |
[HEART BLOCK].
Topics: Adams-Stokes Syndrome; Cardiovascular Diseases; Electrocardiography; Heart Block; Heparin; Humans; I | 1964 |
MYOCARDIAL INFARCTION AFTER SERUM SICKNESS FROM TETANUS ANTITOXIN.
Topics: Adrenocorticotropic Hormone; Cardiovascular Diseases; Cortisone; Drug Therapy; Electrocardiography; | 1964 |
[THE TREATMENT OF ATRIOVENTRICULAR BLOCS WITH STEROIDS AND ACTH].
Topics: Adrenocorticotropic Hormone; Cardiovascular Diseases; Heart Block; Prednisone; Steroids | 1964 |
PROLONGED SHOCK AFTER MYOCARDIAL INFARCTION RELIEVED BY ACTH AND CORTISONE.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adrenocorticotropic Hormone; Cardiovascular Diseases; Co | 1964 |
Glucocorticoids and insulin sensitivity in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Female; Glucocorticoids; Humans; Hyperinsulinism; Ma | 2004 |
Immunosuppression for dual kidney transplantation with marginal organs: the old is better yet.
Topics: Calcineurin Inhibitors; Cardiovascular Diseases; Cyclosporine; Delayed Graft Function; Drug Therapy, | 2007 |
Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Female; Humans; Immunosuppressive Agents; Mal | 2008 |
Conversion from cyclosporin to azathioprine after kidney transplantation.
Topics: Apolipoproteins A; Azathioprine; Cardiovascular Diseases; Cyclosporine; Drug Therapy, Combination; H | 1995 |
[Endocardial fibroelastosis (E.F.) and its differential diagnosis].
Topics: Cardiomyopathies; Cardiomyopathy, Hypertrophic; Cardiovascular Diseases; Catheterization; Child; Dia | 1976 |
Treatment of elderly-onset rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Cardiovascular Diseases; Humans; Osteoporosis; Prednisone | 1991 |
The adrenal glands of elderly men in relation to abnormal prostatic growth. An analysis in an autopsy series.
Topics: Adenoma; Adrenal Gland Neoplasms; Adrenal Glands; Adrenal Medulla; Adult; Aged; Autopsy; Body Height | 1973 |
A self-medication program for cardiology inpatients.
Topics: Aged; Attitude; Cardiovascular Diseases; Evaluation Studies as Topic; Female; Hospitals, Teaching; H | 1972 |
Diuretics and digitalis in the treatment of chronic asthma.
Topics: Aged; Asthma; Bronchitis; Cardiovascular Diseases; Digitalis Glycosides; Diuretics; Humans; Middle A | 1965 |
[Experimental results on the diabetogenic effect of fluprednisolone in the corticoid-glucose-tolerance-test].
Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Dexamethasone; Diabetes Mellitus; Fluprednisolo | 1969 |